Cabaletta Bio Reports 2025 Full Year and Q4 Results: Key Advances in Autoimmune Cell Therapy and Major Clinical Milestones Ahead

Overview

Cabaletta Bio, Inc. (Nasdaq: CABA), a late-stage clinical biotechnology company specializing in curative targeted cell therapies for autoimmune diseases, has released its financial results for the fourth quarter and full year ended December 31, 2025, along with a pivotal business update. This report contains several noteworthy developments that may influence shareholder value and the company’s stock price.

Key Points and Potential Price-Sensitive News

• Rese-cel (resecabtagene autoleucel) Advancements:
  • The company’s lead investigational therapy, rese-cel, is progressing with multiple registrational and pivotal trials across various autoimmune indications, including myositis, systemic lupus erythematosus (SLE), pemphigus vulgaris (PV), systemic sclerosis (SSc), and myasthenia gravis (MG).
  • A Biologics License Application (BLA) submission for myositis is targeted for 2027, supported by a 17-patient registrational cohort with an outpatient dosing option.
  • Novel “no-preconditioning” program enrolling in SLE and PV, with initial RESET-SLE™ readout expected in H1 2026 and durability data from both RESET-SLE and RESET-PV® throughout 2026.
  • Pivotal trial designs for SLE and lupus nephritis (LN) announced (each single-arm, ~25 patients); SSc design expected H1 2026. The outcome of FDA design discussions and no-preconditioning data will inform pivotal decisions across the rese-cel program.
• Automated Manufacturing with Cellares:
  • Cabaletta is implementing automated manufacturing of rese-cel using Cellares’ Cell Shuttle™ platform in the RESET clinical program. This could allow the company to scale up to thousands of patients per year with minimal capital investment and lower labor costs, a significant advantage for future commercialization.
  • First clinical experience with Cellares-produced rese-cel is anticipated in H1 2026. Longer-term clinical data are expected in the second half of 2026.
• Clinical Data and Safety Profile:
  • Recent publications and presentations highlight a strong safety profile for rese-cel in autoimmune indications. Notably, 95% of the first 40 patients treated with preconditioning experienced no or only Grade 1 cytokine release syndrome (CRS); 95% experienced no immune effector cell-associated neurotoxicity.
  • Complete Phase 1/2 data from RESET-SSc™, RESET-SLE, and RESET-MG trials (with preconditioning) will be presented in H1 2026. RESET-MG data will feature as an oral presentation at the American Academy of Neurology (AAN) Annual Meeting in April 2026.
  • These data will be crucial for ongoing FDA discussions regarding registrational pathways, particularly for SSc and MG.
• Financial Position and Capital Resources:
  • Research and development (R&D) expenses increased to \$36.2 million in Q4 2025 and \$142.7 million for the full year, compared to \$25.5 million and \$97.2 million in 2024.
  • General and administrative (G&A) expenses were \$6.4 million in Q4 and \$29.6 million for 2025, versus \$8.3 million and \$27.9 million in 2024.
  • Cash, cash equivalents, and short-term investments stood at \$133.6 million as of December 31, 2025, down from \$164.0 million at year-end 2024. However, an additional \$30 million was raised in Q1 2026 through ATM sales and warrant exercises, extending the cash runway into Q4 2026.
  • Net loss for 2025 was \$167.9 million (\$2.10 per share), up from \$115.9 million (\$2.34 per share) in 2024.

What Shareholders Must Know

• Upcoming Data Readouts and Regulatory Catalysts: The near-term pipeline is rich with value inflection points, including pivotal data releases and regulatory interactions that could significantly impact Cabaletta’s valuation and share price.
• Manufacturing Innovation: The transition to automated manufacturing with Cellares could greatly enhance scalability, reduce costs, and accelerate market readiness for rese-cel if successful in clinical implementation.
• Safety Profile: Favorable safety data compared to CAR T cell therapies in oncology may differentiate rese-cel and support its use in outpatient settings, broadening the addressable market and adoption.
• Financial Outlook: While R&D investment is substantial, the company’s capital position remains solid through late 2026, providing runway for multiple clinical and regulatory milestones.

Forward-Looking Statements and Risks

The company’s outlook is subject to several risks, including regulatory uncertainties, the possibility that early clinical results may not predict long-term outcomes, risks around trial enrollment, trial design modifications, and manufacturing implementation. Investors should closely monitor upcoming data disclosures and FDA interactions as these could materially affect share value.

Financial Summary (Select Figures)

Conclusion

Cabaletta Bio’s 2025 results and business update signal a transformative period ahead, with multiple clinical catalysts and strategic innovations that could materially impact the company’s market valuation. Investors should pay close attention to the upcoming clinical readouts and regulatory updates in 2026, as well as the progress in automated manufacturing and outpatient therapy delivery. The combination of near-term data, regulatory milestones, and scalable manufacturing represents a potentially significant opportunity for value creation—or volatility—depending on execution and outcomes.

Disclaimer: This article is for informational purposes only and does not constitute financial advice or a recommendation to buy or sell any securities. Investors should conduct their own due diligence and consult with financial advisors before making investment decisions. All forward-looking statements are subject to risks and uncertainties as outlined by Cabaletta Bio in their filings with the SEC.

View Cabaletta Bio, Inc. Historical chart here